ACM
SPRB

Aisling Capital Management’s Spruce Biosciences SPRB Stock Holding History

Aisling Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,073
Closed -$948K – 16
2024
Q1 		$948K Hold
16,073
– – 0.32% 14
2023
Q4 		$3.53M Hold
16,073
– – 1.05% 8
2023
Q3 		$2.72M Hold
16,073
– – 1.12% 10
2023
Q2 		$2.59M Hold
16,073
– – 1.27% 10
2023
Q1 		$2.66M Hold
16,073
– – 1.28% 11
2022
Q4 		$1.32M Hold
16,073
– – 0.87% 11
2022
Q3 		$1.65M Hold
16,073
– – 1.1% 11
2022
Q2 		$2.1M Hold
16,073
– – 1.5% 12
2022
Q1 		$2.42M Hold
16,073
– – 1.31% 14
2021
Q4 		$5.38M Hold
16,073
– – 1.9% 14
2021
Q3 		$7.25M Hold
16,073
– – 1.44% 13
2021
Q2 		$13.5M Hold
16,073
– – 2.16% 7
2021
Q1 		$20M Hold
16,073
– – 3.6% 5
2020
Q4 		$29.3M Buy
+16,073
New +$26.6M 5.03% 4

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Aisling Capital Management's SPRB Position: Q2 2024 in Review

Aisling Capital Management sold out of Spruce Biosciences (SPRB) in Q2 2024, closing a stake of 16,073 shares — an estimated $948K sold.

Aisling Capital Management first reported a position in SPRB in Q4 2020 and held it in 14 quarters. The position peaked at $29.3M in Q4 2020. 37 funds tracked by Wall St. Rank hold SPRB as of Q2 2024.

  • Aisling Capital Management reported no remaining Spruce Biosciences position as of Q2 2024 after selling out during the quarter.
  • Aisling Capital Management sold 16,073 Spruce Biosciences shares in Q2 2024, an estimated $948K.
  • Aisling Capital Management first reported a position in Spruce Biosciences in Q4 2020 and held it in 14 quarters.
  • Aisling Capital Management's Spruce Biosciences position peaked at $29.3M in Q4 2020.
  • 37 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2024.

Based on Aisling Capital Management's 13F filing for Q2 2024, filed 8 Aug 2024.